Search 

Personalis, Inc. headquartered in Menlo Park California, USA, Was established in 2011 as a Stanford University spin-out by a team of internationally-renown Next Generation Sequencing (NGS) thought leaders to provide advanced genomic sequencing and analytics solutions to support the development of personalized cancer vaccines and cancer immunotherapies by providing more comprehensive molecular data bout each patient’s cancer and immune response. The Personalis ImmunoID NeXT Platform TM is designed to adapt to the complex and evolving understanding of cancer, providing its biopharmaceutical customers with information on all of the approximately 20,000 human genes, together with the immune system, from a single tissue sample The Personalis Clinical Laboratory in Menlo Park, Califonria is GxP aligned as well as CLIA’88-certified and CAP-accredited.

On 10 June 2020 Personalis, Inc announced a partnership with Berry Genomics with plans to expand operations in PRC with a wholly-owned subsidiary in Shanghai. Berry will provide sequencing services and local support to Personalis operation in Shanghai. Personalis, Inc was granted approval for a business license for Shanghai Personalis Biotechnology Co, LTD on 15 October 2020. The expansion to China includes buildout of a laboratory operation for local customers to use its ImmunoID Next Platform, a commercial team to support local customers and general and administrative functions.

About TOT BIOPHARM International Company Limited
(HKG:1875)

TOT BIOPHARM is dedicated to developing and commercializing innovative cancer drugs and therapies, striving to build a leading brand of oncology treatments trusted by patients and their families as well as medical professionals.

The Group has in place three major integrated technology platforms:

Therapeutic Monoclonal Antibody and Antibody Drug Conjugates (ADCs) Technology Platform: it integrates research and development (R&D) and production capacities for antibody drugs and ADCs, with the designed production capacity of the commercialization base of biological drugs reaching 16,000L to accommodate high-quality commercialization of drug candidates;

Gene Engineering Based Therapeutics Technology Platform: it integrates anti-tumor immunotherapy, gene therapy and viral therapy and pursues R&D and production of tumor-targeted oncolytic virus products;

Innovative Drug Delivery Technology Platform: We have developed an innovative drug delivery system, including an advanced targeted liposome drug delivery system.

Using these platforms, the Group has studied and developed various anti-tumor drug series, and formed a high quality and comprehensive drug product chain. Currently, the Group has 12 drugs under research and development. On top of developing innovative proprietary drugs, TOT BIOPHARM also draws on its own industry value chain to build a complete industry chain platform that supports from R&D, clinical development to production and marketing. By adopting an open platform business model, it is able to cooperate with biomedical enterprises and third parties in different stages along its industry value chain.

Zhongyuan Yuzi is a provincial investment company and a province-managed state-owned corporation, the establishment of which is approved by Henan provincial government, with the function of serving the strategy and market operation and the role in safeguarding the investment of provincial infrastructure projects,cultivating and guiding the strategic emerging industries, leading and inciting the social investments.

Currently, we are looking for leading pharmaceutical companies as long-term financial or strategic investment partnerships.

河南省骨干企业。先后发起设立了3000亿元规模的河南省新型城镇化发展基金、1000亿元规模的“一带一路（河南）发展基金”、 1000亿元规模的全省现代服务业基金、50亿元规模的PPP开发性基金。

截至2019年12月底，豫资控股集团注册资金100亿元，合并总资产2734.9亿，净资产845.57亿。豫资控股集团子公司及孙公司（并表子公司）共计67家，其中二级子公司11家，三级子公司56家。国内评级AAA、国际评级A2。